Replies to post #186717 on Biotech Values

[DewDiligence]

8% assumes the entire GT1 ESRX population would be captured, not just the 25% in the exclusive ABBV deal. So, this is quite a stretch.

Huh? 25M is the number of lives insured by clients who use ESRX’s national formulary (not the total number of lives handled by ESRX)—see #msg-110049781.

25M lives is 8% of the US population.